Sobi Maintains Grip On RSV Market – For Now
Though Competition Is Coming
Vaccines and new antibody drugs are set to transform the respiratory syncytial virus space but for now, the Swedish rare disease specialist’s 25-year old offering Synagis is enjoying increased demand.
